Factors associated with subtherapeutic levels of valproic acid in hospitalized patients with epilepsy: A retrospective cohort study

Tuanthon Boonlue,Papitchaya Sitsuer,Wasinee Phosri,Warisara Jinatongthai

DOI: https://doi.org/10.1097/md.0000000000040488

IF: 1.6

2024-11-13

Medicine

Abstract:Valproic acid (VPA) is one of the most widely used anti-seizure medications (ASMs) for the treatment of various types of seizures. [ 1 ] It is also used in the treatment of bipolar disorder, schizoaffective disorders, neuropathic pain, and migraine prevention. [ 2 ] However, the monitoring and measurement of VPA levels are crucial due to its narrow therapeutic range. The therapeutic levels for treating epilepsy are 50–100 and 50–125 mg/L when used as mood stabilizers. [ 3 ] If the concentration exceeds these levels, it may lead to toxicity, whereas concentrations below these levels may render treatment ineffective. Given the narrow therapeutic range of VPA, therapeutic drug monitoring (TDM) should be implemented to ensure its efficacy and safety in epilepsy treatment. In Thailand, pharmacists can utilize interpreted drug-level information by advising physicians to monitor drug levels and adjust individual dosage regimens accordingly. [ 4 ] To our knowledge, multiple pharmacokinetic mechanisms affect VPA levels, such as drug interactions, medical comorbidities, genetic polymorphisms, and perhaps formulations and rarely autoinduction. [ 5 ] The interpretation of VPA levels is essential to consider factors influencing drug levels because of the unpredictable relationship between dose and VPA levels. [ 6 ]

medicine, general & internal